RxDoctor Payments Data

Anna Martin, NP

Acute Care · Bridgeton, MONPI 1558060541

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) at 35.8% of the total. 2025 is the largest year on record at $746, 2.9 times the $254 reported in 2023.

$1,359in general payments, 2019–2025

Across 80 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$486
  • Pfizer$253
  • AstraZeneca$133
  • Phathom Pharmaceuticals, Inc.$125
  • Novo Nordisk$125
  • Abiomed$124
  • plus $113 from 1 others

What the payments were for

  • Food & beverage$1,359100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,359 in reported general payments places this provider in the 80th percentile of 272 acute care providers in Missouri.

See all acute care providers in Missouri

Medicare billing

Part B allowed, 2024
$10,548
Medicare patients
100
Services billed
147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban98$100,909
EntrestoSacubitril/Valsartan23$26,065
XareltoRivaroxaban20$20,336
Dofetilide58$8,715
Metoprolol Succinate189$2,919
Midodrine Hcl20$1,850
Diltiazem 24hr Er (Cd)Diltiazem Hcl19$1,277
Amiodarone Hcl12$638
Potassium Chloride18$450
Spironolactone46$367
Metoprolol Tartrate36$311
Furosemide52$198
Carvedilol30$176
Cephalexin24$157
Losartan Potassium24$121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$253$100,90998 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 272 acute care providers in Missouri.

Other acute care in Bridgeton

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →